Soleno Therapeutics Inc.
Soleno Therapeutics Announces Executive Compensation and Severance Plan Updates
Summary
On January 21, 2026, Soleno Therapeutics, Inc. announced that its Board of Directors approved increases to the base salaries and cash bonuses for fiscal year 2025 and certain equity awards for its named executive officers, including the Chief Executive Officer, Chief Financial Officer, Chief Commercial Officer, and Senior Vice President of Regulatory Affairs. Additionally, the Board approved a new Key Executive Change in Control and Severance Plan, which provides for severance payments and benefits, including equity acceleration, in the event of certain qualifying terminations, both outside of and in connection with a change in control of the Company.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement